Gene patents still alive and kicking: their impact on provision of genetic testing for long QT syndrome in the Canadian public health-care system

摘要: PurposeAlthough the Supreme Court of United States limited their availability in Association for Molecular Pathology v. Myriad Genetics, gene patents remain important around world. We examine situation Canada, where continue to exist, light recent litigation relating familial long QT syndrome (LQTS).MethodsWe conducted in-depth semistructured interviews with 25 stakeholders across five Canadian provinces and supplemented this a case analysis litigation.ResultsThe majority LQTS testing was carried out outside Canada. Rising costs prompted several attempt repatriate testing. However, stymied efforts, particularly more centralized, increasing lowering innovation. It context that hospital launched test against patents, resulting novel agreement free hospitals from effects patents.ConclusionOur reveals rapidly evolving genetic provision landscape under pressure strained budgets poor collaboration. The resulted blueprint public use throughout Canada's health-care system, but it will only have value if governments are proactive its use.